Table 3.

Summary of most common TRAEs reported in ≥ 20% of patients

		AE, n (%)				≥ Grade III AE
	12 mg (n = 4)	10 mg (n = 4)	Total	12 mg (n = 4)	10 mg (n = 4)		Total
TRAEs	4 (100.0)	4 (100.0)	8 (100.0)	4 (100.0)	1 (25.0)		5 (62.5)
Appetite down	4 (100.0)	3 (75.0)	7 (87.5)	0 (0.0)	0 (0.0)		2 (25.0)
Hypertriglyceridemia	2 (50.0)	3 (75.0)	5 (62.5)	0 (0.0)	0 (0.0)		0 (0.0)
Alanine transaminase elevation	3 (75.0)	2 (50.0)	5 (62.5)	0 (0.0)	0 (0.0)		0 (0.0)
Aspartate transaminase elevation	2 (50.0)	3 (75.0)	5 (62.5)	0 (0.0)	0 (0.0)		0 (0.0)
Hypertension	3 (75.0)	1 (25.0)	4 (50.0)	2 (50.0)	0 (0.0)		2 (25.0)
Thrombocytopenia	2 (50.0)	2 (50.0)	4 (50.0)	0 (0.0)	1 (25.0)		1 (12.5)
Nausea	1 (25.0)	3 (75.0)	4 (50.0)	0 (0.0)	0 (0.0)		0 (0.0)
Fatigue	2 (50.0)	2 (50.0)	4 (50.0)	0 (0.0)	0 (0.0)		0 (0.0)
Neutropenia	1 (25.0)	2 (50.0)	3 (37.5)	0 (0.0)	0 (0.0)		0 (0.0)
Hypercholesterolemia	1 (25.0)	2 (50.0)	3 (37.5)	0 (0.0)	0 (0.0)		0 (0.0)
Leukopenia	0 (0.0)	3 (75.0)	3 (37.5)	0 (0.0)	0 (0.0)		0 (0.0)
Dizziness	1 (25.0)	2 (50.0)	3 (37.5)	0 (0.0)	0 (0.0)		0 (0.0)
Hand-foot syndrome	2 (50.0)	0 (0.0)	2 (25.0)	1 (25.0)	0 (0.0)		1 (12.5)
Diarrhea	2 (50.0)	0 (0.0)	2 (25.0)	1 (25.0)	0 (0.0)		1 (12.5)
Vomiting	2 (50.0)	0 (0.0)	2 (25.0)	0 (0.0)	0 (0.0)		0 (0.0)
Gum pain	1 (25.0)	1 (25.0)	2 (25.0)	0 (0.0)	0 (0.0)		0 (0.0)
Proteinuria	1 (25.0)	1 (25.0)	2 (25.0)	0 (0.0)	0 (0.0)		0 (0.0)
Hypothyroidism	1 (25.0)	1 (25.0)	2 (25.0)	0 (0.0)	0 (0.0)		0 (0.0)
Anemia	0 (0.0)	2 (50.0)	2 (25.0)	0 (0.0)	0 (0.0)		0 (0.0)
Hoarseness	1 (25.0)	1 (25.0)	2 (25.0)	0 (0.0)	0 (0.0)		0 (0.0)
Thyroid stimulating hormone elevation	2 (50.0)	0 (0.0)	2 (25.0)	0 (0.0)	0 (0.0)		0 (0.0)

AE adverse event, TRAEs treatment-related adverse events